Helix Acquisition Corp - Ordinary Shares - Class A

NASDAQ:HLXA  
9.99
+0.07 (+0.71%)
Debt Financing / Related, Mergers / Acquisitions, Equity Financing / Related

Moonlake Immunotherapeutics AG And Helix Acquisition Corp. Announce Business Combination Agreement

Published: 10/04/2021 12:05 GMT
Helix Acquisition Corp - Ordinary Shares - Class A (HLXA) - Moonlake Immunotherapeutics Ag and Helix Acquisition Corp.
Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab.
Helix Acquisition Corp.
- Leading Institutional Investors Commit $115 Million Through a Pipe Led by Cormorant Asset Management.
Helix Acquisition Corp.
- Transaction Also Includes Commitments for a $115 Million Pipe at $10.00 per Share.
Helix Acquisition Corp.
- Upon Closing of Business Combination, Moonlake Will Have Access to Approximately $230 Million in Cash.